Veterinary Therapeutic Antibodies Gain Momentum—Biotech Teams Step Up to Meet Industry Demand

"There's also a growing movement away from antibiotics and toward precision medicine when it comes to treating disease in animals—whether companion pets or livestock." According to a scientist at Biovenic, which is a biotechnology company working on improving veterinary healthcare. "With mounting concerns about antimicrobial resistance and a global push for animal welfare, veterinary monoclonal antibodies are becoming the next big thing in animal health."

Regulatory frameworks are evolving to accommodate this promising class of biologics, but there's one catch: development requires specialized expertise and technologies.

Closing the Gap Between Research and Application

That's where Biovenic steps in—to provide researchers and animal health companies with the tools they need to bring antibody therapies from bench to bedside, which has built a full-service veterinary antibody discovery and engineering platform tailored to the unique needs of veterinary applications.

From camelids to canines, the platform supports a variety of species and targets, making it easier than ever for researchers to move from target validation to preclinical proof-of-concept.

Smarter Starts, Hot Targets

Kicking off a antibody discovery project is easier with a solid target—and an established database of hot veterinary targets gives researchers a serious leg up. From cytokines involved in canine atopic dermatitis to viral antigens in bovine respiratory diseases, Biovenic's catalog includes dozens of validated, high-interest targets backed by immunogenicity data and literature support, represented by oncologic targets like receptor tyrosine kinases, immune checkpoints, oncogenic mutations, and tumor-associated antigens, allergy targets like IL-31, and infection targets like canine parvovirus.

From Concept to Custom Therapeutics

A streamlined pipeline that walks clients through epitope mapping stands as the core of the custom therapeutic antibody development offering, to accommodate antibody discovery, engineering, and production for clients' specific animal model and indication—whether it's generating neutralizing antibodies for viral infections in horses or blocking inflammatory markers in feline arthritis.

Three Platforms, One Unified Mission

Biovenic offers three integrated discovery platforms to tackle the technical challenges of veterinary antibody R&D
* Hybridoma: Classic yet effective, which allows rapid generation of murine monoclonals. Particularly useful when immunogenicity is low or when quick screening is needed.
* Single B Cell So: Offers unparalleled precision and diversity isolating antigen-specific B cells from immunized animals .
* Phage Display: Allows for vast diversity and engineering flexibility when libraries matter. Ideal for exotic species or hard-to-immunize hosts.

Future of Animal Health—Biologics

The rise of veterinary antibodies is a paradigm shift in how people usually think about animal care, not just a passing trend. From minimizing antibiotic use to delivering species-specific biologics, the possibilities are wide open. Visit https://www.biovenic.com/ to learn more.

About
Biovenic is a trustworthy partner for researchers, startups, or established animal health firms looking to step into the evolving space of animal biologics.